文献速递消化道肿瘤放疗放疗物理与技术

剂量学参数与胰腺癌SBRT后十二指肠病理损伤的相关性

Dosimetric parameters correlate with duodenal histopathologic damage after stereotactic body radiotherapy for pancreatic cancer: Secondary analysis of a prospective clinical trial.
PubMed 文献 · Radiother Oncol · 2017-01-12

该研究基于一项胰腺癌I期前瞻性试验的二次分析,纳入13例SBRT后接受手术的可切除患者,评估十二指肠剂量学参数与病理/临床毒性的关系。结果显示十二指肠组织学损伤与十二指肠平均剂量、V20-V35及PTV平均/最大剂量相关,而临床毒性未显示与剂量学参数或病理损伤相关。

要点

  • 十二指肠组织学损伤与十二指肠平均剂量及V20-V35相关。
  • PTV平均剂量和最大剂量与十二指肠病理损伤相关。
  • 临床毒性未显示与剂量学参数或十二指肠病理损伤相关。

核心结论

  • 十二指肠组织学损伤与十二指肠平均剂量、V20-V35及PTV平均/最大剂量相关。

研究设计与样本

  • SBRT方案为5次每日5-8Gy,同期联合奈非那韦。

主要发现

  • 十二指肠中位平均剂量和最大剂量分别为20Gy和37Gy。
  • 十二指肠中位V5-V40分别为64、62、52、39、27、14、5和0cc。
  • 十二指肠损伤评分中位为2分(1分4例,2分8例,3分1例)。
  • 较高的十二指肠损伤评分与较高的十二指肠平均剂量(r=0.75,p=0.003)、V35(r=0.61,p=0.03)、V30(r=0.67,p=0.01)、V25(r=0.68,p=0.01)、V20(r=0.56,p=0.05)及PTV平均剂量(r=0.59,p=0.03)和最大剂量(r=0.61,p=0.03)相关。
  • 临床毒性未显示与剂量学参数或十二指肠病理损伤相关。

关键数值与推荐

  • 十二指肠病理损伤采用预定标准评估:1级无/轻微,2级中度,3级显著损伤。
  • 临床毒性按CTCAE评估。

临床怎么用

  • 胰腺癌SBRT计划设计时需关注十二指肠平均剂量及V20-V35,以降低组织学损伤风险。
  • PTV平均剂量和最大剂量也与十二指肠病理损伤相关,优化靶区剂量分布可能有助于保护十二指肠。

局限性

  • 分析仅基于13例接受手术的可切除患者,样本量小。
  • 临床毒性未显示与剂量学参数或病理损伤相关,可能受样本量限制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Prospectively assess relationships between dosimetric parameters and histopathologic/clinical duodenal toxicities in patients on a phase I trial for pancreatic cancer. METHODS: Forty-six borderline resectable/unresectable patients were enrolled on a prospective trial testing neoadjuvant gemcitabine/5-fluorouracil followed by SBRT (5 daily fractions of 5-8Gy) and concurrent nelfinavir. Post-SBRT surgery was performed in 13 resectable patients, which constituted the patient population herein. Pathologic duodenal damage was assessed using predetermined criteria: 1, no/minimal; 2, moderate; and 3, marked damage. Clinical toxicities were assessed per the Clinical Terminology Criteria for Adverse Events (CTCAE). Duodenal dosimetric parameters included V5-V40 and mean/maximum doses. Spearman correlation and linear regression evaluated associations between dosimetric parameters and clinical/pathologic duodenal toxicity. RESULTS: The median duodenal mean and maximum doses were 20 and 37Gy. Median duodenal V5-V40 were 64, 62, 52, 39, 27, 14, 5 and 0cc, respectively. The median duodenal damage score was 2 (four 1, eight 2, and one 3). Higher duodenal damage scores correlated with higher duodenal mean doses (r=0.75, p=0.003), V35 (r=0.61, p=0.03), V30 (r=0.67, p=0.01), V25 (r=0.68, p=0.01), V20 (r=0.56, p=0.05), and the planning target volume (PTV) mean (r=0.59, p=0.03) and maximum (r=0.61, p=0.03) doses. Clinical toxicities did not correlate with dosimetric parameters or duodenal pathologic damage. CONCLUSIONS: Duodenal histologic damage correlates with mean duodenal dose, V20-V35, and PTV mean/maximum doses.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Verma V, Lazenby AJ, Zheng D, et al. Dosimetric parameters correlate with duodenal histopathologic damage after stereotactic body radiotherapy for pancreatic cancer: Secondary analysis of a prospective clinical trial. Radiother Oncol. 2017. PMID: 28089484. doi:10.1016/j.radonc.2016.12.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。